The same effect, but in a different mechanism, was reported with miR-200b-3p in colorectal cancer, where, via targeting TUBB3, it reduced resistance to oxaliplatin and promoted apoptosis and growth inhibition in resistant cancer cells (247). Here, TUBB3 is linked to cancer.